| Rheumatoid Arthritis |
1 |
0.29 |
| Immunization |
0 |
0.94 |
| Patient Safety |
0 |
0.28 |
| Pneumococcal Infection |
0 |
0.24 |
| Vaccines |
0 |
0.24 |
| Disease-Modifying Antirheumatic Drugs |
0 |
0.19 |
| Glucocorticoid |
0 |
0.19 |
| Adverse Effects |
0 |
0.13 |
| Enzyme-Linked Immunosorbent Assay (ELISA) |
0 |
0.11 |
| Immunoglobulin G (IgG) |
0 |
0.11 |
| Arthritis |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Fever |
0 |
0.06 |
| France |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Immunoglobulin A (IgA) |
0 |
0.06 |
| Immunosuppressive Therapy |
0 |
0.06 |
| Steroids |
0 |
0.06 |
| Translational Research |
0 |
0.06 |
| X-ray |
0 |
0.06 |